1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    002603   CNE1000015S0

SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

(002603)
  Report
End-of-day quote Shenzhen Stock Exchange  -  05-18
23.10 CNY   -1.91%
05/02Yiling Pharmaceutical's Q1 Profit Tumbles 28% as Sales Plummet
MT
04/29Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021
CI
04/28Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

HS Bio Sdn. Bhd. Enters into MOU with Shijiazhuang Yiling Pharmaceutical Co., Ltd

07/05/2021 | 09:22am EDT

Hong Seng Consolidated Berhad's announcements made on 4 November 2020, 9 November 2020, 18 March 2021 and 18 June 2021 in relation to the Memorandum of Understanding (“MOU”) entered into between HS Bio Sdn. Bhd. (formerly known as HS Bio Supplies Sdn. Bhd.) (“HS Bio”) (a wholly-owned subsidiary of the Company) and Shijiazhuang Yiling Pharmaceutical Co., Ltd. (“Yiling Pharmaceutical”) (“Announcements”), and unless otherwise defined, the definitions set out in the Announcements shall apply herein. Further to the Announcements, the Board wishes to inform that the Parties to the MOU have mutually decided not to renew this particular MOU as this MOU was intended for the Parties to obtain the relevant approval from the Ministry of Health Malaysia (“MOH”) for the registration of Yiling Pharmaceutical’s therapeutic product (i.e. Lianhua Qingwen Capsule) in Malaysia after the product successfully obtained approval for use in Singapore, United States and some European countries. However, despite the Parties’ joint efforts, Malaysia’s health industry laws and regulation does not allow for the said product to be registered due to certain prohibited ingredients. As such, since the term of the MOU expired on 3 July 2021, the Parties have mutually agreed to terminate the MOU (“Termination”). The Termination will not have any material impact on the issued share capital, substantial shareholders’ shareholdings, net assets, gearing, earnings and earnings per share of Hong Seng Group for the financial year ending 30 September 2021. Nevertheless, the Parties are currently exploring to bring in other Yiling Pharmaceutical’s products that may be relevant and beneficial for Malaysians.


© S&P Capital IQ 2021
Stocks mentioned in the article
ChangeLast1st jan.
MSCI SINGAPORE (GDTR) -0.33% 5547.45 Real-time Quote.-11.35%
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. -1.91% 23.1 End-of-day quote.17.86%
All news about SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
05/02Yiling Pharmaceutical's Q1 Profit Tumbles 28% as Sales Plummet
MT
04/29Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year ..
CI
04/28Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Qua..
CI
04/18Yiling Pharma's Shares Sink on Doubts Over COVID-19 Drug Efficacy
MT
2021Shunten International Limited Enters into Cooperation Framework Agreement with Shijiazh..
CI
2021Shijiazhuang Yiling Pharmaceutical Co., Ltd. announced a financing transaction
CI
2021Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year..
CI
2021HS Bio Sdn. Bhd. Enters into MOU with Shijiazhuang Yiling Pharmaceutical Co., Ltd
CI
2021Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces 2020 Final Distribution Plan to ..
CI
2021Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Dividend for the Year 2020
CI
More news
Financials
Sales 2022 12 094 M 1 802 M 1 802 M
Net income 2022 1 642 M 245 M 245 M
Net Debt 2022 - - -
P/E ratio 2022 23,6x
Yield 2022 -
Capitalization 38 660 M 5 760 M 5 760 M
Capi. / Sales 2022 3,20x
Capi. / Sales 2023 2,71x
Nbr of Employees 15 155
Free-Float 40,9%
Chart SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
Duration : Period :
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 23,10 CNY
Average target price 31,49 CNY
Spread / Average Target 36,3%
EPS Revisions
Managers and Directors
Xiang Jun Wu Director & General Manager-Marketing Center
Chen Guang Li Chief Financial Officer & Director
Yi Ling Wu Chairman
Xue Dong Gao Chairman-Supervisory Board
Zhen Wang Independent Director